These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Malignant hyperthermia in China. Xu ZH; Luo AL; Guo XY; Ren HZ; Wang YL; Zhang X; Huang YG; Ye TH Anesth Analg; 2006 Oct; 103(4):983-5. PubMed ID: 17000816 [TBL] [Abstract][Full Text] [Related]
10. [Atypical malignant hyperthermia. A higher incidence than expected]. Herrero E; Casinello F; de Stefano J; Fernández-Guisasola J; Pérez-Gallardo A Rev Esp Anestesiol Reanim; 1996 Jan; 43(1):42-3. PubMed ID: 8851836 [No Abstract] [Full Text] [Related]
11. The Israeli Diagnostic Center for Malignant Hyperthermia: 7-years' accumulated experience. Glauber V; Ben Abraham R; Zweig A; Perel A Isr J Med Sci; 1997 Oct; 33(10):643-7. PubMed ID: 9397136 [TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621 [TBL] [Abstract][Full Text] [Related]
13. Malignant hyperthermia and severe hypoglycemia after reexposure to halothane. Bichel T; Canivet JL; Damas P; Lamy M Acta Anaesthesiol Belg; 1994; 45(1):23-7. PubMed ID: 8209622 [TBL] [Abstract][Full Text] [Related]